These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 10883887)

  • 41. Production and characterisation of a novel chicken IgY antibody raised against C-terminal peptide from human thymidine kinase 1.
    Wu C; Yang R; Zhou J; Bao S; Zou L; Zhang P; Mao Y; Wu J; He Q
    J Immunol Methods; 2003 Jun; 277(1-2):157-69. PubMed ID: 12799048
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Concentration of thymidine kinase 1 in serum (S-TK1) is a more sensitive proliferation marker in human solid tumors than its activity.
    He Q; Zhang P; Zou L; Li H; Wang X; Zhou S; Fornander T; Skog S
    Oncol Rep; 2005 Oct; 14(4):1013-9. PubMed ID: 16142366
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Thymidine kinase 1 in serum predicts increased risk of distant or loco-regional recurrence following surgery in patients with early breast cancer.
    He Q; Fornander T; Johansson H; Johansson U; Hu GZ; Rutqvist LE; Skog S
    Anticancer Res; 2006; 26(6C):4753-9. PubMed ID: 17214336
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.
    Bagegni N; Thomas S; Liu N; Luo J; Hoog J; Northfelt DW; Goetz MP; Forero A; Bergqvist M; Karen J; Neumüller M; Suh EM; Guo Z; Vij K; Sanati S; Ellis M; Ma CX
    Breast Cancer Res; 2017 Nov; 19(1):123. PubMed ID: 29162134
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The clinical significance of thymidine kinase 1 measurement in serum of breast cancer patients using anti-TK1 antibody.
    He Q; Zou L; Zhang PA; Lui JX; Skog S; Fornander T
    Int J Biol Markers; 2000; 15(2):139-46. PubMed ID: 10883887
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Thymidine kinase 1 as a tumor biomarker: technical advances offer new potential to an old biomarker.
    Jagarlamudi KK; Shaw M
    Biomark Med; 2018 Sep; 12(9):1035-1048. PubMed ID: 30039979
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative aspects of the proliferation marker thymidine kinase 1 in human and canine tumour diseases.
    von Euler H; Eriksson S
    Vet Comp Oncol; 2011 Mar; 9(1):1-15. PubMed ID: 21303450
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Thymidine kinase and cancer monitoring.
    Aufderklamm S; Todenhöfer T; Gakis G; Kruck S; Hennenlotter J; Stenzl A; Schwentner C
    Cancer Lett; 2012 Mar; 316(1):6-10. PubMed ID: 22068047
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Anti-malignin antibody evaluation: a possible challenge for cancer management.
    Botti C; Martinetti A; Nerini-Molteni S; Ferrari L
    Int J Biol Markers; 1997; 12(4):141-7. PubMed ID: 9582602
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The proliferation marker thymidine kinase 1 in clinical use.
    Zhou J; He E; Skog S
    Mol Clin Oncol; 2013 Jan; 1(1):18-28. PubMed ID: 24649117
    [TBL] [Abstract][Full Text] [Related]  

  • 51.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 52.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 53.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 54.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 3.